Figure 8.

Projections for PASC prevalence are more sensitive to infection duration and the fraction of infections developing PASC than the infection prevalence. All simulations assume a combined efficacy against PASC of ${\text{VE}}_{\mathrm{T}}=0.55$, and illustrate the possible outcomes attained through different combinations of primary and secondary efficacy. The prevalence of infection increases across the rows, the fraction of infections developing PASC increases down the columns, and the duration of infection changes within each panel (according to colour). PASC duration is modelled with an exponential distribution with mean ${\rho }^{-1}=1$ year. Other parameters as in figure 3.